Whitehawk reports FY2025 net loss $20.6M (incl $87.3M gain); cash $145.7M, two Phase 1 ADCs

Whitehawk Therapeutics, Inc.

FY2025 net loss $20.6M includes $87.3M gain on AADI divestiture; Q4 net loss $23.3M vs $18.3M prior-year quarter.
Cash, equivalents and ST investments $145.7M at YE2025 (up from $47.2M); cash runway into 2028.
HWK-007 (PTK7) and HWK-016 (MUC16) ADCs both actively recruiting Phase 1 trials in lung, ovarian, endometrial cancers.
HWK-206 IND submission for small-cell lung cancer and neuroendocrine tumors planned mid-2026; Phase 1 start Q3 2026.
Margaret Dugan appointed CMO in December 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Whitehawk Therapeutics, Inc. reported the full-year ended December 31, 2025 results: net income $20.6 million.

Period: the full-year ended December 31, 2025
Net income: $20.6 million
Result: reported results

Exact text from the filing

Net loss for the full-year ended December 31, 2025, was $20.6 million, as compared to $63.7 million for the same period in 2024.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Whitehawk Therapeutics, Inc. reported the three months ended December 31, 2025 results: net income $23.3 million.

Period: the three months ended December 31, 2025
Net income: $23.3 million
Result: reported results

Exact text from the filing

Net loss for the three months ended December 31, 2025, was $23.3 million as compared to $18.3 million for the three months ended December 31, 2024.

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-103117

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.